<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2019//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_190101.dtd">
<PubmedArticleSet>
  <PubmedArticle>
    <MedlineCitation Status="PubMed-not-MEDLINE" Owner="NLM">
      <PMID Version="1">35304684</PMID>
      <DateRevised>
        <Year>2022</Year>
        <Month>05</Month>
        <Day>24</Day>
      </DateRevised>
      <Article PubModel="Print-Electronic">
        <Journal>
          <ISSN IssnType="Print">2198-6576</ISSN>
          <JournalIssue CitedMedium="Print">
            <Volume>9</Volume>
            <Issue>3</Issue>
            <PubDate>
              <Year>2022</Year>
              <Month>Jun</Month>
            </PubDate>
          </JournalIssue>
          <Title>Rheumatology and therapy</Title>
          <ISOAbbreviation>Rheumatol Ther</ISOAbbreviation>
        </Journal>
        <ArticleTitle>Usability Study of PF-06410293, an Adalimumab Biosimilar, by Prefilled Pen: Open-Label, Single-Arm, Sub-Study of a Phase 3 Trial in Patients with Rheumatoid Arthritis.</ArticleTitle>
        <Pagination>
          <StartPage>839</StartPage>
          <EndPage>850</EndPage>
          <MedlinePgn>839-850</MedlinePgn>
        </Pagination>
        <ELocationID EIdType="doi" ValidYN="Y">10.1007/s40744-022-00439-8</ELocationID>
        <Abstract>
          <AbstractText Label="INTRODUCTION" NlmCategory="BACKGROUND">The aim of this sub-study was to evaluate injection success of patients with rheumatoid arthritis (RA) and their caregivers administering the adalimumab (ADL) biosimilar, PF-06410293 (ADL-PF: adalimumab-afzb; Abrilada<sup>®</sup>/Amsparity<sup>®</sup>/Xilbrilada<sup>®</sup>) by prefilled pen (PFP) during the open-label treatment period in year two (weeks 52-78) of a phase 3 multinational, double-blind, clinical study (NCT02480153) comparing ADL-PF and reference ADL (Humira<sup>®</sup>) sourced from the EU.</AbstractText>
          <AbstractText Label="METHODS" NlmCategory="METHODS">This sub-study included adult patients with active RA not adequately controlled by methotrexate. Patients received subcutaneous ADL-PF 40 mg by prefilled syringe (PFS) at weeks 52 and 54, then six biweekly doses (weeks 56-66) of ADL-PF 40 mg each via a single-use PFP device. Training was given on first injection at week 56; all injections were given by patients/caregivers. The primary endpoint was delivery system success rate (DSSR): the percentage of participants (i.e., actual PFP user) achieving delivery success for each of the six attempted PFP injections. Injection success was recorded by the observer (Observer Assessment Tool) and participant (Participant Assessment Tool).</AbstractText>
          <AbstractText Label="RESULTS" NlmCategory="RESULTS">In total, 50 patients with no experience self-injecting with an autoinjector/injection pen were included (74.0% female; mean age at screening, 54.9 years; mean RA duration, 8.0 years). Of these, 49 (98.0%) completed the sub-study and 46 (92.0%) received all six PFP injections. Overall DSSR (n = 294 injections) across visits was 100% (95% CI 92.0-100.0%). Complete injection was confirmed following inspection of 292 used and returned PFPs. A total of 47/49 (95.9%) participants who completed the sub-study elected to continue study treatment using PFP injections, rather than switching back to the PFS.</AbstractText>
          <AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">All actual PFP users could safely and effectively administer ADL-PF by PFP at each visit, and nearly all participants who completed the sub-study elected to continue study treatment using PFP injections.</AbstractText>
          <AbstractText Label="TRIAL REGISTRATION" NlmCategory="BACKGROUND">ClinicalTrials.gov identifier: NCT02480153; EudraCT number: 2014-000352-29.</AbstractText>
          <CopyrightInformation>© 2022. The Author(s).</CopyrightInformation>
        </Abstract>
        <AuthorList CompleteYN="Y">
          <Author ValidYN="Y">
            <LastName>Fleischmann</LastName>
            <ForeName>Roy M</ForeName>
            <Initials>RM</Initials>
            <Identifier Source="ORCID">0000-0002-6630-1477</Identifier>
            <AffiliationInfo>
              <Affiliation>University of Texas Southwestern Medical Center at Dallas, Metroplex Clinical Research Center, Dallas, TX, USA. rfleischmann@arthdocs.com.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Bock</LastName>
            <ForeName>Amy E</ForeName>
            <Initials>AE</Initials>
            <AffiliationInfo>
              <Affiliation>Pfizer Inc, Cambridge, MA, USA.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Zhang</LastName>
            <ForeName>Wuyan</ForeName>
            <Initials>W</Initials>
            <AffiliationInfo>
              <Affiliation>Pfizer Inc, Lake Forest, IL, USA.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Godfrey</LastName>
            <ForeName>Charles M</ForeName>
            <Initials>CM</Initials>
            <AffiliationInfo>
              <Affiliation>Pfizer R&amp;D UK Ltd, Cambridge, UK.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Vranic</LastName>
            <ForeName>Ivana</ForeName>
            <Initials>I</Initials>
            <AffiliationInfo>
              <Affiliation>Pfizer, Tadworth, UK.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Cronenberger</LastName>
            <ForeName>Carol</ForeName>
            <Initials>C</Initials>
            <AffiliationInfo>
              <Affiliation>Pfizer Inc, Collegeville, PA, USA.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Dokoupilová</LastName>
            <ForeName>Eva</ForeName>
            <Initials>E</Initials>
            <AffiliationInfo>
              <Affiliation>Medical Plus, s.r.o., Uherske Hradiste, Czech Republic.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>Department of Pharmaceutical Technology, Faculty of Pharmacy, Masaryk University, Brno, Czech Republic.</Affiliation>
            </AffiliationInfo>
          </Author>
        </AuthorList>
        <Language>eng</Language>
        <DataBankList CompleteYN="Y">
          <DataBank>
            <DataBankName>ClinicalTrials.gov</DataBankName>
            <AccessionNumberList>
              <AccessionNumber>NCT02480153</AccessionNumber>
            </AccessionNumberList>
          </DataBank>
        </DataBankList>
        <PublicationTypeList>
          <PublicationType UI="D016428">Journal Article</PublicationType>
        </PublicationTypeList>
        <ArticleDate DateType="Electronic">
          <Year>2022</Year>
          <Month>03</Month>
          <Day>18</Day>
        </ArticleDate>
      </Article>
      <MedlineJournalInfo>
        <Country>England</Country>
        <MedlineTA>Rheumatol Ther</MedlineTA>
        <NlmUniqueID>101674543</NlmUniqueID>
        <ISSNLinking>2198-6576</ISSNLinking>
      </MedlineJournalInfo>
      <KeywordList Owner="NOTNLM">
        <Keyword MajorTopicYN="Y">Adalimumab</Keyword>
        <Keyword MajorTopicYN="Y">Autoinjector</Keyword>
        <Keyword MajorTopicYN="Y">Biosimilar</Keyword>
        <Keyword MajorTopicYN="Y">PF-06410293</Keyword>
        <Keyword MajorTopicYN="Y">Prefilled pen</Keyword>
        <Keyword MajorTopicYN="Y">Rheumatoid arthritis</Keyword>
      </KeywordList>
    </MedlineCitation>
    <PubmedData>
      <History>
        <PubMedPubDate PubStatus="received">
          <Year>2021</Year>
          <Month>12</Month>
          <Day>13</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="accepted">
          <Year>2022</Year>
          <Month>3</Month>
          <Day>3</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="pubmed">
          <Year>2022</Year>
          <Month>3</Month>
          <Day>20</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="medline">
          <Year>2022</Year>
          <Month>3</Month>
          <Day>20</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="entrez">
          <Year>2022</Year>
          <Month>3</Month>
          <Day>19</Day>
          <Hour>5</Hour>
          <Minute>32</Minute>
        </PubMedPubDate>
      </History>
      <PublicationStatus>ppublish</PublicationStatus>
      <ArticleIdList>
        <ArticleId IdType="pubmed">35304684</ArticleId>
        <ArticleId IdType="doi">10.1007/s40744-022-00439-8</ArticleId>
        <ArticleId IdType="pii">10.1007/s40744-022-00439-8</ArticleId>
      </ArticleIdList>
      <ReferenceList>
        <Reference>
          <Citation>Lapadula G, Marchesoni A, Armuzzi A, et al. Adalimumab in the treatment of immune-mediated diseases. Int J Immunopathol Pharmacol. 2014;27:33–48.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1177/03946320140270S103</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>AbbVie. HUMIRA (adalimumab): prescribing information. 2021. http://www.rxabbvie.com/pdf/humira.pdf . Accessed 17 May 2021.</Citation>
        </Reference>
        <Reference>
          <Citation>European Medicines Agency. HUMIRA (adalimumab): summary of product characteristics. 2021. https://www.ema.europa.eu/en/documents/product-information/humira-epar-product-information_en.pdf . Accessed 17 May 2021.</Citation>
        </Reference>
        <Reference>
          <Citation>Armuzzi A, Lionetti P, Blandizzi C, et al. Anti-TNF agents as therapeutic choice in immune-mediated inflammatory diseases: focus on adalimumab. Int J Immunopathol Pharmacol. 2014;27:11–32.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1177/03946320140270S102</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>US Food and Drug Administration. Scientific considerations in demonstrating biosimilarity to a reference product: guidance for industry. 2015. https://www.fda.gov/media/82647/download . Accessed 17 May 2021.</Citation>
        </Reference>
        <Reference>
          <Citation>European Medicines Agency. Guideline on similar biological medicinal products containing monoclonal antibodies– non-clinical and clinical issues. 2012. https://www.ema.europa.eu/en/documents/scientific-guideline/guideline-similar-biological-medicinal-products-containing-monoclonal-antibodies-non-clinical_en.pdf . Accessed 17 May 2021.</Citation>
        </Reference>
        <Reference>
          <Citation>World Health Organization. Application to add anti-TNFs to the World Health Organization’s Essential Medicines List. https://www.who.int/selection_medicines/committees/expert/22/applications/s8.1_TNF-alfa-inhibitors.pdf . Accessed 19 October 2021.</Citation>
        </Reference>
        <Reference>
          <Citation>Putrik P, Ramiro S, Kvien TK, et al. Inequities in access to biologic and synthetic DMARDs across 46 European countries. Ann Rheum Dis. 2014;73:198–206.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1136/annrheumdis-2012-202603</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Smolen JS, Goncalves J, Quinn M, Benedetti F, Lee JY. Era of biosimilars in rheumatology: reshaping the healthcare environment. RMD Open. 2019;5:e000900.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1136/rmdopen-2019-000900</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>European Medicines Agency. Amsparity (adalimumab): summary of production characteristics. 2020. https://www.ema.europa.eu/en/documents/product-information/amsparity-epar-product-information_en.pdf . Accessed 26 February 2020.</Citation>
        </Reference>
        <Reference>
          <Citation>Pfizer Inc. Abrilada™ (adalimumab-afzb): prescribing information. 2019. http://labeling.pfizer.com/ShowLabeling.aspx?id=12780 . Accessed 26 February 2020.</Citation>
        </Reference>
        <Reference>
          <Citation>Pfizer Canada ULC. Abrilada (adalimumab injection): product monograph including patient medication information. 2021. https://www.pfizer.ca/sites/default/files/202107/Abrilada_PM_EN_252317_29-Jun-2021.pdf . Accessed 13 August 2021.</Citation>
        </Reference>
        <Reference>
          <Citation>Wyeth. Xilbrilada® (adalimumabe): prescribing information. 2021. https://www.pfizer.com.br/sites/default/files/inline-files/Xilbrilada_Profissional_de_Saude_08.pdf . Accessed 15 October 2021.</Citation>
        </Reference>
        <Reference>
          <Citation>SwissMedic. Abrilada®, solution for injection in pre-filled pen. https://www.swissmedicinfo.ch/ShowText.aspx?textType=PI&amp;lang=DE&amp;authNr=67831 . Accessed 25 October 2021.</Citation>
        </Reference>
        <Reference>
          <Citation>The National Administration of Drugs FaMDAA. Referencia: EX-2019–51618513-APN-DGA#ANMAT. 2020. http://www.anmat.gov.ar/boletin_anmat/Febrero_2020/Dispo_0755-20.pdf . Accessed 26 October 2021.</Citation>
        </Reference>
        <Reference>
          <Citation>Fleischmann RM, Alten R, Pileckyte M, et al. A comparative clinical study of PF-06410293, a candidate adalimumab biosimilar, and adalimumab reference product (Humira(R)) in the treatment of active rheumatoid arthritis. Arthritis Res Ther. 2018;20:178.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1186/s13075-018-1676-y</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Fleischmann RM, Alvarez DF, Bock AE, et al. Randomised study of PF-06410293, an adalimumab (ADL) biosimilar, compared with reference ADL for the treatment of active rheumatoid arthritis: results from weeks 26–52, including a treatment switch from reference ADL to PF-06410293. RMD Open. 2021;7:e001578.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1136/rmdopen-2021-001578</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Fleischmann RM, Alvarez DF, Bock AE, et al. Long-term efficacy, safety, and immunogenicity of the adalimumab biosimilar, PF-06410293, in patients with rheumatoid arthritis after switching from reference adalimumab (Humira(R)) or continuing biosimilar therapy: week 52–92 data from a randomized, double-blind, phase 3 trial. Arthritis Res Ther. 2021;23:248.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1186/s13075-021-02626-4</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Borras-Blasco J, Gracia-Perez A, Rosique-Robles JD, Castera MD, Abad FJ. Acceptability of switching adalimumab from a prefilled syringe to an autoinjection pen. Expert Opin Biol Ther. 2010;10:301–7.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1517/14712590903530633</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Corominas H, Garcia-Diaz S, Sanchez-Eslava L, Figuls R. Switching adalimumab from syringe to pen. Expected outcomes. Expert Opin Biol Ther. 2012;12:805–6.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1517/14712598.2012.676033</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kivitz A, Baret-Cormel L, van Hoogstraten H, et al. Usability and patient preference phase 3 study of the sarilumab pen in patients with active moderate-to-severe rheumatoid arthritis. Rheumatol Ther. 2018;5:231–42.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1007/s40744-017-0090-2</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kivitz A, Cohen S, Dowd JE, et al. Clinical assessment of pain, tolerability, and preference of an autoinjection pen versus a prefilled syringe for patient self-administration of the fully human, monoclonal antibody adalimumab: the TOUCH trial. Clin Ther. 2006;28:1619–29.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.clinthera.2006.10.006</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kivitz A, Segurado OG. HUMIRA pen: a novel autoinjection device for subcutaneous injection of the fully human monoclonal antibody adalimumab. Expert Rev Med Devices. 2007;4:109–16.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1586/17434440.4.2.109</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Little RD, Chu IE, van der Zanden EP, et al. Comparison of adalimumab serum drug levels when delivered by pen versus syringe in patients with inflammatory bowel disease. An international, multicentre cohort analysis. J Crohns Colitis. 2019;13:1527–36.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1093/ecco-jcc/jjz103</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Muller-Ladner U, Flipo RM, Vincendon P, Brault Y, Kielar D. Comparison of patient satisfaction with two different etanercept delivery systems. A randomised controlled study in patients with rheumatoid arthritis. Z Rheumatol. 2012;71:890–9.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1007/s00393-012-1034-4</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Rekaya N, Vicik SM, Hulesch BT, McDonald LL. Enhancement of an auto-injector device for self-administration of etanercept in patients with rheumatoid arthritis confers emotional and functional benefits. Rheumatol Ther. 2020;7:537–52.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1007/s40744-020-00216-5</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Fierce Biotech. Press release: HUMIRA receives FDA approval for treatment of Crohn's disease. 2007. https://www.fiercebiotech.com/biotech/press-release-humira-receives-fda-approval-for-treatment-of-crohn-s-disease . Accessed 25 October 2021.</Citation>
        </Reference>
        <Reference>
          <Citation>Paulson S. Assessment of relative bioavailability, safety, and tolerability of single doses of adalimumab administered via an autoinjector pen and a prefilled syringe. J Am Acad Derm. 2007;56:AB9.</Citation>
        </Reference>
        <Reference>
          <Citation>Barbosa CM, Rodriguez de Castro B, Labeaga Beramendi Y, Terroba Alonso P, Barbazan Vazquez J. Patient satisfaction survey: substitution of reference etanercept with a biosimilar product. Eur J Hosp Pharm. 2021;28:109–11.</Citation>
        </Reference>
        <Reference>
          <Citation>Blauvelt A, Gordon KB, Lee P, et al. Efficacy, safety, usability, and acceptability of risankizumab 150 mg formulation administered by prefilled syringe or by an autoinjector for moderate to severe plaque psoriasis. J Dermatolog Treat. 2021. https://www.tandfonline.com/doi/full/10.1080/09546634.2021.1914812 .</Citation>
        </Reference>
        <Reference>
          <Citation>Fettner S, Mela C, Wildenhahn F, et al. Evidence of bioequivalence and positive patient user handling of a tocilizumab autoinjector. Expert Opin Drug Deliv. 2019;16:551–61.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1080/17425247.2019.1604678</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Rho YH, Rychlewska-Hanczewska A, Sliwowska B, Kim TH. Usability of prefilled syringe and autoinjector for SB4 (an etanercept biosimilar) in patients with rheumatoid arthritis. Adv Ther. 2019;36:2287–95.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1007/s12325-019-01027-z</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Fenwick S, Thakur K, Munro D. Nurse and patient perceptions and preferences for subcutaneous autoinjectors for inflammatory joint or bowel disease: findings from a European survey. Rheumatol Ther. 2019;6:195–206.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1007/s40744-019-0144-8</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Ghil J, Zielinska A, Lee Y. Usability and safety of SB5 (an adalimumab biosimilar) prefilled syringe and autoinjector in patients with rheumatoid arthritis. Curr Med Res Opin. 2019;35:497–502.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1080/03007995.2018.1560211</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Bernstein D, Pavord ID, Chapman KR, et al. Usability of mepolizumab single-use prefilled autoinjector for patient self-administration. J Asthma. 2020;57:987–98.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1080/02770903.2019.1630641</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Callis Duffin K, Bukhalo M, Bobonich MA, et al. Usability of a novel disposable autoinjector device for ixekizumab: results from a qualitative study and an open-label clinical trial, including patient-reported experience. Med Devices (Auckl). 2016;9:361–9.</Citation>
        </Reference>
        <Reference>
          <Citation>Cohen S, Klimiuk PA, Krahnke T, Assudani D. Successful administration of BI 695501, an adalimumab biosimilar, using an autoinjector (AI): results from a phase II open-label clinical study (VOLTAIRE((R))-RL). Expert Opin Drug Deliv. 2018;15:545–8.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1080/17425247.2018.1472572</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Collier DH, Bitman B, Coles A, Liu L, Kumar S, Judd C. A novel electromechanical autoinjector, AutoTouch, for self-injection of etanercept: real-world use and benefits. Postgrad Med. 2017;129:118–25.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1080/00325481.2017.1251291</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Cox DS, Alvarez DF, Bock AE, Cronenberger CL. Randomized, open-label, single-dose, parallel-group pharmacokinetic study of PF-06410293 (adalimumab-afzb), an adalimumab biosimilar, by subcutaneous dosing using a prefilled syringe or a prefilled pen in healthy subjects. Clin Pharmacol Drug Dev. 2021;10:1166–73.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1002/cpdd.939</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Aletaha D, Neogi T, Silman AJ, et al. 2010 rheumatoid arthritis classification criteria: an American College of Rheumatology/European League Against Rheumatism collaborative initiative. Arthritis Rheum. 2010;62:2569–81.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1002/art.27584</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Clopper CJP, Pearson ES. The use of confidence intervals or fiducial limits illustrated in the case of binomial. Biometrika. 1934;26:404–13.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1093/biomet/26.4.404</ArticleId>
          </ArticleIdList>
        </Reference>
      </ReferenceList>
    </PubmedData>
  </PubmedArticle>
</PubmedArticleSet>
